Archive · 3 Aug 2026
AstraZeneca, Bristol Myers Squibb Explore $400 Billion Merger
AstraZeneca, a big British drug company, and Bristol Myers Squibb, a big American drug company, are talking about joining together.
If they do, the new company would be worth about $400 billion, which is huge.
The talks have been happening for months, but no final deal has been made yet.
When the news came out, AstraZeneca’s stock fell about 7 % and Bristol Myers Squibb’s stock went up about 4 %.
The merger would make a very large company that sells medicines for cancer and other diseases.
It could become one of the biggest deals ever in the business world.
The companies hope the new size will help them grow and make more money.
The talks are still in the early stages, so nothing is guaranteed yet.
AstraZeneca and Bristol Myers Squibb are in merger talks that could value the combined company at about $400 billion.
The talks have been ongoing for several months, but no formal agreement has been reached.
If completed, the deal would rank among the largest corporate mergers ever.
AstraZeneca shares fell 7 % on Monday, while Bristol Myers Squibb shares rose 3.8 % in U.S. pre‑market trading.
The merger would create a global healthcare giant with strong oncology and rare‑disease portfolios.
- Who
- AstraZeneca and Bristol Myers Squibb
- What
- Merger talks that could create a $400 billion company
- When
- Talks ongoing for several months; news reported Sunday
- Where
- United Kingdom and United States
- Why
- To form a global healthcare giant and benefit from market valuations
- Proposed Deal Value
- $400 billion
- Stock Impact
- AstraZeneca down 7 %, Bristol Myers Squibb up 3.8 %
- Industry
- Pharmaceuticals
- Companies Involved
- AstraZeneca, Bristol Myers Squibb
- Status
- Talks ongoing, no agreement